
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/662229/publications.pdf Version: 2024-02-01



ΜΑΓΑ Κ ΜΑΙΝΙ

#	Article	IF	CITATIONS
1	The Role of Virus-Specific Cd8+ Cells in Liver Damage and Viral Control during Persistent Hepatitis B Virus Infection. Journal of Experimental Medicine, 2000, 191, 1269-1280.	8.5	761
2	Immunotherapies for hepatocellular carcinoma. Nature Reviews Clinical Oncology, 2022, 19, 151-172.	27.6	643
3	Living in the liver: hepatic infections. Nature Reviews Immunology, 2012, 12, 201-213.	22.7	451
4	Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell–mediated liver damage. Journal of Experimental Medicine, 2007, 204, 667-680.	8.5	385
5	Incubation Phase of Acute Hepatitis B in Man: Dynamic of Cellular Immune Mechanisms. Hepatology, 2000, 32, 1117-1124.	7.3	359
6	A global scientific strategy to cure hepatitis B. The Lancet Gastroenterology and Hepatology, 2019, 4, 545-558.	8.1	342
7	Direct ex vivo analysis of hepatitis B virus-specific CD8+ T cells associated with the control of infection. Gastroenterology, 1999, 117, 1386-1396.	1.3	331
8	Temporal Analysis of Early Immune Responses in Patients With Acute Hepatitis B Virus Infection. Gastroenterology, 2009, 137, 1289-1300.	1.3	324
9	IL-10–Producing Regulatory B Cells in the Pathogenesis of Chronic Hepatitis B Virus Infection. Journal of Immunology, 2012, 189, 3925-3935.	0.8	310
10	Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell–mediated deletion. Journal of Experimental Medicine, 2013, 210, 99-114.	8.5	286
11	Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science, 2021, 372, 1418-1423.	12.6	286
12	Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology, 2011, 53, 1494-1503.	7.3	283
13	Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature, 2022, 601, 110-117.	27.8	280
14	IL-2high tissue-resident T cells in the human liver: Sentinels for hepatotropic infection. Journal of Experimental Medicine, 2017, 214, 1567-1580.	8.5	259
15	Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science, 2022, 377, .	12.6	241
16	Upregulation of the Tim-3/Galectin-9 Pathway of T Cell Exhaustion in Chronic Hepatitis B Virus Infection. PLoS ONE, 2012, 7, e47648.	2.5	235
17	Blockade of Immunosuppressive Cytokines Restores NK Cell Antiviral Function in Chronic Hepatitis B Virus Infection. PLoS Pathogens, 2010, 6, e1001227.	4.7	228
18	Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells. Nature Medicine, 2015, 21, 591-600.	30.7	226

#	Article	IF	CITATIONS
19	Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. Journal of Experimental Medicine, 2008, 205, 2111-2124.	8.5	220
20	CXCR6 marks a novel subset of T-betloEomeshi natural killer cells residing in human liver. Scientific Reports, 2016, 6, 26157.	3.3	220
21	Escaping High Viral Load Exhaustion. Journal of Experimental Medicine, 2002, 195, 1089-1101.	8.5	213
22	Modulation of the CD8 ⁺ -T-Cell Response by CD4 ⁺ CD25 ⁺ Regulatory T Cells in Patients with Hepatitis B Virus Infection. Journal of Virology, 2005, 79, 3322-3328.	3.4	212
23	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡. Journal of Hepatology, 2020, 72, 539-557.	3.7	208
24	Circulating and intrahepatic antiviral B cells are defective in hepatitis B. Journal of Clinical Investigation, 2018, 128, 4588-4603.	8.2	208
25	Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. Journal of Hepatology, 2013, 58, 225-233.	3.7	202
26	Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition). European Journal of Immunology, 2021, 51, 2708-3145.	2.9	198
27	Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet, The, 1991, 337, 1061-1062.	13.7	191
28	Bim-mediated deletion of antigen-specific CD8+ T cells in patients unable to control HBV infection. Journal of Clinical Investigation, 2008, 118, 1835-1845.	8.2	187
29	Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. Journal of Hepatology, 2011, 55, 103-110.	3.7	183
30	The Third Signal Cytokine IL-12 Rescues the Anti-Viral Function of Exhausted HBV-Specific CD8 T Cells. PLoS Pathogens, 2013, 9, e1003208.	4.7	176
31	Distinct Metabolic Requirements of Exhausted and Functional Virus-Specific CD8ÂT Cells in the Same Host. Cell Reports, 2016, 16, 1243-1252.	6.4	176
32	Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. Science Immunology, 2020, 5, .	11.9	172
33	Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. Journal of Hepatology, 2015, 62, 486-491.	3.7	160
34	Disease-Promoting Effects of Type I Interferons in Viral, Bacterial, and Coinfections. Journal of Interferon and Cytokine Research, 2015, 35, 252-264.	1.2	154
35	The role of innate immunity in the immunopathology and treatment of HBV infection. Journal of Hepatology, 2016, 64, S60-S70.	3.7	150
36	Sestrins induce natural killer function in senescent-like CD8+ T cells. Nature Immunology, 2020, 21, 684-694.	14.5	139

#	Article	IF	CITATIONS
37	Eomeshi NK Cells in Human Liver Are Long-Lived and Do Not Recirculate but Can Be Replenished from the Circulation. Journal of Immunology, 2016, 197, 4283-4291.	0.8	125
38	T-cell clonality in immune responses. Trends in Immunology, 1999, 20, 262-266.	7.5	115
39	The molecular basis of the failed immune response in chronic HBV: Therapeutic implications. Journal of Hepatology, 2010, 52, 616-619.	3.7	115
40	Clonal Expansions in Acute EBV Infection Are Detectable in the CD8 and not the CD4 Subset and Persist with a Variable CD45 Phenotype. Journal of Immunology, 2000, 165, 5729-5737.	0.8	110
41	NK Cells: A Double-Edged Sword in Chronic Hepatitis B Virus Infection. Frontiers in Immunology, 2013, 4, 57.	4.8	103
42	Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection?. Current Opinion in Immunology, 2000, 12, 403-408.	5.5	100
43	Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial. Lancet, The, 2020, 395, 888-898.	13.7	98
44	HIV-1 Epitope-Specific CD8+ T Cell Responses Strongly Associated with Delayed Disease Progression Cross-Recognize Epitope Variants Efficiently. Journal of Immunology, 2006, 176, 6130-6146.	0.8	97
45	The Host–pathogen Interaction during HBV Infection: Immunological Controversies. Antiviral Therapy, 2010, 15, 15-24.	1.0	96
46	Optimal management of hepatitis B virus infection – EASL Special Conference. Journal of Hepatology, 2015, 63, 1238-1253.	3.7	91
47	Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. Science, 2022, 375, 183-192.	12.6	91
48	IL-15 Overcomes Hepatocellular Carcinoma-Induced NK Cell Dysfunction. Frontiers in Immunology, 2018, 9, 1009.	4.8	88
49	Restoring, releasing or replacing adaptive immunity in chronic hepatitis B. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 662-675.	17.8	87
50	Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men Sexually Transmitted Infections, 1996, 72, 27-31.	1.9	81
51	The Level of Viral Antigen Presented by Hepatocytes Influences CD8 T-Cell Function. Journal of Virology, 2007, 81, 2940-2949.	3.4	80
52	Defective T-cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand. The Lancet Gastroenterology and Hepatology, 2018, 3, 192-202.	8.1	75
53	Longevity and replenishment of human liver-resident memory T cells and mononuclear phagocytes. Journal of Experimental Medicine, 2020, 217, .	8.5	72
54	Fine needle aspirates comprehensively sample intrahepatic immunity. Gut, 2019, 68, 1493-1503.	12.1	65

#	Article	IF	CITATIONS
55	Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection?. Current Opinion in Microbiology, 2000, 3, 387-392.	5.1	64
56	Adaptive Reconfiguration of Natural Killer Cells in HIV-1 Infection. Frontiers in Immunology, 2018, 9, 474.	4.8	64
57	Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS‑CoV-2 infection. EBioMedicine, 2021, 65, 103259.	6.1	61
58	Therapeutic Potential of TLR8 Agonist GSâ€9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators. Hepatology, 2021, 74, 55-71.	7.3	61
59	T cells in COVID-19 — united in diversity. Nature Immunology, 2020, 21, 1307-1308.	14.5	59
60	The impact of viral mutations on recognition by SARS-CoV-2 specific TÂcells. IScience, 2021, 24, 103353.	4.1	57
61	Targeting human Acyl-CoA:cholesterol acyltransferase as a dual viral and TÂcell metabolic checkpoint. Nature Communications, 2021, 12, 2814.	12.8	54
62	Interferon Alpha Induces Sustained Changes in NK Cell Responsiveness to Hepatitis B Viral Load Suppression In Vivo. PLoS Pathogens, 2016, 12, e1005788.	4.7	54
63	Hepatitis B infection: current concepts and future challenges. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 109-113.	0.5	53
64	Human Liver Memory CD8+ T Cells Use Autophagy for Tissue Residence. Cell Reports, 2020, 30, 687-698.e6.	6.4	53
65	Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B—Report From the 2019 EASLâ€AASLD HBV Treatment Endpoints Conference. Hepatology, 2020, 71, 1070-1092.	7.3	52
66	Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients. Journal of Hepatology, 2021, 74, 1064-1074.	3.7	52
67	Blood transcriptional biomarkers of acute viral infection for detection of pre-symptomatic SARS-CoV-2 infection: a nested, case-control diagnostic accuracy study. Lancet Microbe, The, 2021, 2, e508-e517.	7.3	52
68	A comparison of two techniques for the molecular tracking of specific Tâ€cell responses; CD4+human Tâ€cell clones persist in a stable hierarchy but at a lower frequency than clones in the CD8+population. Immunology, 1998, 94, 529-535.	4.4	48
69	Alternative splicing of hepatitis B virus: A novel virus/host interaction altering liver immunity. Journal of Hepatology, 2017, 67, 687-699.	3.7	47
70	CD4+ T-lymphocyte telomere length is related to fibrosis stage, clinical outcome and treatment response in chronic hepatitis C virus infection. Journal of Hepatology, 2010, 53, 252-260.	3.7	46
71	T cell receptor usage of virus-specific CD8 cells and recognition of viral mutations during acute and persistent hepatitis B virus infection. European Journal of Immunology, 2000, 30, 3067-3078.	2.9	45
72	Innate and Adaptive Immune Responses in Hepatitis B Virus Infection. Digestive Diseases, 2010, 28, 126-132.	1.9	45

#	Article	IF	CITATIONS
73	Characterisation and induction of tissue-resident gamma delta T-cells to target hepatocellular carcinoma. Nature Communications, 2022, 13, 1372.	12.8	44
74	Effect of HIV Infection and Antiretroviral Therapy on Hepatitis B Virus (HBV)–Specific T Cell Responses in Patients Who Have Resolved HBV Infection. Journal of Infectious Diseases, 2005, 191, 1169-1179.	4.0	43
75	Greater CD8+ TCR Heterogeneity and Functional Flexibility in HIV-2 Compared to HIV-1 Infection. Journal of Immunology, 2003, 171, 307-316.	0.8	42
76	T Cells Infiltrating Diseased Liver Express Ligands for the NKG2D Stress Surveillance System. Journal of Immunology, 2017, 198, 1172-1182.	0.8	41
77	Liver sampling: a vital window into HBV pathogenesis on the path to functional cure. Gut, 2018, 67, gutjnl-2017-314873.	12.1	40
78	Molecular fingerprinting reveals non-overlapping T cell oligoclonality between an inflamed site and peripheral blood. International Immunology, 1999, 11, 535-543.	4.0	39
79	Reconstitution of Hepatitis B Virus (HBV)–Specific T Cell Responses with Treatment of Human Immunodeficiency Virus/HBV Coinfection. Journal of Infectious Diseases, 2003, 188, 1815-1819.	4.0	36
80	Rapid synchronous type 1 IFN and virus-specific TÂcell responses characterize first wave non-severe SARS-CoV-2 infections. Cell Reports Medicine, 2022, 3, 100557.	6.5	36
81	The influence of T cell cross-reactivity on HCV-peptide specific human T cell response. Hepatology, 2006, 43, 602-611.	7.3	35
82	T cell receptor-therapy in HBV-related hepatocellularcarcinoma. OncoImmunology, 2015, 4, e1008354.	4.6	34
83	Oxidative Stress Triggers Selective tRNA Retrograde Transport in Human Cells during the Integrated Stress Response. Cell Reports, 2019, 26, 3416-3428.e5.	6.4	34
84	Rare inborn errors associated with chronic hepatitis B virus infection*. Hepatology, 2012, 56, 1661-1670.	7.3	30
85	Cholesterol-modifying drugs in COVID-19. Oxford Open Immunology, 2020, 1, iqaa001.	2.8	27
86	Immuneâ€Mobilizing Monoclonal T Cell Receptors Mediate Specific and Rapid Elimination of Hepatitis B–Infected Cells. Hepatology, 2020, 72, 1528-1540.	7.3	26
87	Platelets harness the immune response to drive liver cancer. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 12840-12841.	7.1	25
88	Spatiotemporal Differences in Presentation of CD8 T Cell Epitopes during Hepatitis B Virus Infection. Journal of Virology, 2019, 93, .	3.4	25
89	Natural Killer Cells in Liver Disease. Seminars in Liver Disease, 2017, 37, 198-209.	3.6	24
90	SARS-CoV-2–specific memory B cells can persist in the elderly who have lost detectable neutralizing antibodies. Journal of Clinical Investigation, 2022, 132, .	8.2	24

#	Article	IF	CITATIONS
91	The past, current and future epidemiological dynamic of SARS-CoV-2. Oxford Open Immunology, 2022, 3,	2.8	24
92	Complementary Effects of Interleukin-15 and Alpha Interferon Induce Immunity in Hepatitis B Virus Transgenic Mice. Journal of Virology, 2016, 90, 8563-8574.	3.4	22
93	The Design and Development of a Multi-HBV Antigen Encoded in Chimpanzee Adenoviral and Modified Vaccinia Ankara Viral Vectors; A Novel Therapeutic Vaccine Strategy against HBV. Vaccines, 2020, 8, 184.	4.4	21
94	Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver. Molecular Therapy, 2018, 26, 2553-2566.	8.2	20
95	Differences in the regulation of CD4 and CD8 T–cell clones during immune responses. Philosophical Transactions of the Royal Society B: Biological Sciences, 2000, 355, 401-406.	4.0	19
96	Harnessing alveolar macrophages for sustained mucosal T-cell recall confers long-term protection to mice against lethal influenza challenge without clinical disease. Mucosal Immunology, 2014, 7, 89-100.	6.0	19
97	The human liver microenvironment shapes the homing and function of CD4 ⁺ T-cell populations. Gut, 2022, 71, 1399-1411.	12.1	19
98	NK cells limit therapeutic vaccine–induced CD8 ⁺ T cell immunity in a PD-L1–dependent manner. Science Translational Medicine, 2022, 14, eabi4670.	12.4	19
99	HLAâ€DR polymorphism in SARS oVâ€2 infection and susceptibility to symptomatic COVIDâ€19. Immunology, 2022, 166, 68-77.	4.4	18
100	Defective natural killer cell anti-viral capacity in paediatric HBV infection. Clinical and Experimental Immunology, 2015, 179, 466-476.	2.6	16
101	Immunological biomarker discovery in cure regimens for chronic hepatitis B virus infection. Journal of Hepatology, 2022, 77, 525-538.	3.7	16
102	Licensing Virus-Specific T Cells to Secrete the Neutrophil Attracting Chemokine CXCL-8 during Hepatitis B Virus Infection. PLoS ONE, 2011, 6, e23330.	2.5	15
103	TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis. Scientific Reports, 2017, 7, 5514.	3.3	14
104	CRISPR-Mediated Base Conversion Allows Discriminatory Depletion of Endogenous T Cell Receptors for Enhanced Synthetic Immunity. Molecular Therapy - Methods and Clinical Development, 2020, 19, 149-161.	4.1	14
105	Human antiviral B cell responses: Emerging lessons from hepatitis B and COVIDâ€19. Immunological Reviews, 2021, 299, 108-117.	6.0	14
106	Systemic inflammation and residual viraemia in HIV-positive adults on protease inhibitor monotherapy: a cross-sectional study. BMC Infectious Diseases, 2015, 15, 138.	2.9	13
107	Global and immunotherapeutic insights into hepatitis B. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 71-72.	17.8	13
108	ULBP1 Is Elevated in Human Hepatocellular Carcinoma and Predicts Outcome. Frontiers in Oncology, 2020, 10, 971.	2.8	10

#	Article	IF	CITATIONS
109	Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. Science, 2021, , eabm0811.	12.6	10
110	Liver-resident memory T cells: life in lockdown. Seminars in Immunopathology, 2022, 44, 813-825.	6.1	10
111	Regulation of apoptosis and replicative senescence in CD8+ T cells from patients with viral infections. Biochemical Society Transactions, 2000, 28, 255-258.	3.4	8
112	IL-2–Engineered nano-APC Effectively Activates Viral Antigen-Mediated T Cell Responses from Chronic Hepatitis B Virus-Infected Patients. Journal of Immunology, 2012, 188, 1534-1543.	0.8	8
113	Direct-acting antivirals trump interferon-alpha in their capacity to rescue exhausted T cells upon HCV clearance. Journal of Hepatology, 2014, 61, 459-461.	3.7	8
114	Cirrhosis Hampers Early and Rapid Normalization of Natural Killer Cell Phenotype and Function in Hepatitis C Patients Undergoing Interferon-Free Therapy. Frontiers in Immunology, 2020, 11, 129.	4.8	7
115	HIV-1 Vpr drives a tissue residency-like phenotype during selective infection of resting memory TÂcells. Cell Reports, 2022, 39, 110650.	6.4	6
116	Hepatitis B assessment without hepatitis B virus DNA quantification: a prospective cohort study in Uganda. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2019, 113, 11-17.	1.8	5
117	Pathogenesis of hepatitis B virus infection and potential for new therapies. British Journal of Hospital Medicine (London, England: 2005), 2012, 73, 581-584.	0.5	4
118	Liver-resident CD8+ T cells: Learning lessons from the local experts. Journal of Hepatology, 2020, 72, 1049-1051.	3.7	4
119	Reply to: "To target or not to target viral antigens in HBV related HCC?― Journal of Hepatology, 2015, 62, 1450-1452.	3.7	3
120	FRI-162-Prime-boost vaccination strategies using chimpanzee-adeno and MVA viral vectored vaccines encoding multiple HBV antigens (CPmutS) and class II invariant chain molecular adjuvants induces robust T-cell and anti-HBs antibody response in mice. Journal of Hepatology, 2019, 70, e459-e460.	3.7	2
121	CD8+ T cells cure without killing. Nature Reviews Immunology, 2019, 19, 201-201.	22.7	2
122	Isolation of human intrahepatic leukocytes for phenotypic and functional characterization by flow cytometry. STAR Protocols, 2022, 3, 101356.	1.2	2
123	Shared immunotherapeutic approaches in HIV and hepatitis B virus. Current Opinion in HIV and AIDS, 2020, 15, 157-164.	3.8	1
124	The Effects of Pathogens on the Immune System: Viral Hepatitis. , 2006, , 233-254.		0
125	Immunity to Oncogenic Viruses. , 2016, , 363-374.		0